Enrique Grande, Director of the Medical Oncology Department at Quirónsalud, and Adjunct Professor at The University of Texas MD Anderson Cancer Center, shared a post on X:
“IL-15 enters bladder cancer. N-803 (Anktiva), an IL-15 superagonist, is now approved with BCG for BCG-unresponsive high-risk NMIBC (CIS ± papillary disease), the first cytokine approved in oncology in >30 years. Editorial revisits the path from IL-2 to IL-15 and what this means for future immunotherapy.”
Title: IL-15: from discovery to FDA approval
Authors: Zihai Li, John Wrangle, Kai He, Jonathan Sprent, Mark P. Rubinstein
You Can Also Read: Patrick Soon-Shiong: 30 Years and $3B Toward a Universal Cancer Fighter
